Neurocognitive enhancement: what can we do and what should we do?

被引：330
|
作者：
Farah, MJ
Illes, J
Cook-Deegan, R
Gardner, H
Kandel, E
King, P
Parens, E
Sahakian, B
Wolpe, PR
机构：
[1] Univ Penn, Ctr Cognit Neurosci, Philadelphia, PA 19104 USA
[2] Stanford Univ, Ctr Biomed Eth, Stanford, CA 94304 USA
[3] Stanford Univ, Dept Radiol, Stanford, CA 94304 USA
[4] Duke Univ, Inst Genome Sci & Policy, Ctr Genome Eth Law & Policy, Durham, NC 27708 USA
[5] Duke Univ, Dept Publ Policy Studies, Durham, NC 27708 USA
[6] Harvard Univ, Grad Sch Educ, Cambridge, MA 02138 USA
[7] Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA
[8] Howard Hughes Med Inst, New York, NY 10032 USA
[9] Georgetown Univ, Ctr Law, Washington, DC 20001 USA
[10] Hastings Ctr, Garrison, NY 10524 USA
[11] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England
[12] Univ Penn, Ctr Bioeth, Dept Psychiat, Philadelphia, PA 19104 USA
[13] Univ Penn, Ctr Bioeth, Dept Med Eth, Philadelphia, PA 19104 USA
[14] Univ Penn, Ctr Bioeth, Dept Sociol, Philadelphia, PA 19104 USA
来源：
NATURE REVIEWS NEUROSCIENCE | 2004年 / 5卷 / 05期
基金：
美国国家卫生研究院; 美国国家科学基金会;
关键词：
D O I：
10.1038/nrn1390
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Our growing ability to alter brain function can be used to enhance the mental processes of normal individuals as well as to treat mental dysfunction in people who are ill. The prospect of neurocognitive enhancement raises many issues about what is safe, fair and otherwise morally acceptable. This article resulted from a meeting on neurocognitive enhancement that was held by the authors. Our goal is to review the state of the art in neurocognitive enhancement, its attendant social and ethical problems, and the ways in which society can address these problems.
引用
收藏
页码：421 / 425
页数：5
相关论文
共 50 条
  • [1] Neurocognitive enhancement: what can we do and what should we do?
    Martha J. Farah
    Judy Illes
    Robert Cook-Deegan
    Howard Gardner
    Eric Kandel
    Patricia King
    Eric Parens
    Barbara Sahakian
    Paul Root Wolpe
    [J]. Nature Reviews Neuroscience, 2004, 5 : 421 - 425
  • [2] What we do, what we should do, and what we should not do
    Ernst, E
    [J]. ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2001, 7 (04) : 36 - +
  • [3] Atrial fibrillation:: What can we do, what should we do, and what must we do?
    Gjesdal, K
    [J]. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2005, 39 (06) : 324 - 326
  • [4] Prevention and Pharmacovigilance What Should We Do, What Can We Do?
    Edwards, I. Ralph
    [J]. DRUG SAFETY, 2012, 35 (02) : 87 - 90
  • [5] The Regional Distribution of Rheumatologists: What Can We Do, What Should We Do?
    Deal, Chad L.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3011 - 3013
  • [6] What can we do and what should we do from a legal standpoint?
    Hérait, P
    [J]. EUROCANCER 2002, 2002, : 157 - 157
  • [7] Prevention and PharmacovigilanceWhat Should We Do, What Can We Do?
    I. Ralph Edwards
    [J]. Drug Safety, 2012, 35 : 87 - 90
  • [8] The evaluation of innovation in radiation oncology - what can we do and what should we do?
    Pignol, Jean-Philippe
    Janus, Cecile
    [J]. ACTA ONCOLOGICA, 2015, 54 (09) : 1251 - 1253
  • [9] COMPUTER-APPLICATIONS IN THE SCHOOLS - WHAT WE CAN DO - WHAT WE SHOULD DO
    MASTERSON, JJ
    [J]. LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS, 1995, 26 (03) : 211 - 212
  • [10] What We Can and Should Do Foreword
    Ende, Jack
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2022, 106 (05) : XVII - XVIII
12345